Abeona Therapeutics (NASDAQ:ABEO) SVP Brendan O’malley Sells 4,826 Shares

Posted by George Bondi on Jun 9th, 2026

Abeona Therapeutics Inc. (NASDAQ:ABEO – Get Free Report) SVP Brendan O’malley sold 4,826 shares of the firm’s stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $5.43, for a total value of $26,205.18. Following the transaction, the senior vice president directly owned 446,308 shares in the company, valued at approximately $2,423,452.44. This represents a 1.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Abeona Therapeutics Price Performance

NASDAQ ABEO traded up $0.07 on Tuesday, reaching $5.45. 1,159,558 shares of the company’s stock traded hands, compared to its average volume of 981,006. The stock has a market cap of $310.60 million, a PE ratio of 5.62 and a beta of 1.35. Abeona Therapeutics Inc. has a 12 month low of $4.00 and a 12 month high of $7.54. The stock has a 50-day simple moving average of $5.37 and a 200 day simple moving average of $5.16. The company has a debt-to-equity ratio of 0.03, a current ratio of 5.89 and a quick ratio of 5.70.

Abeona Therapeutics (NASDAQ:ABEO – Get Free Report) last announced its quarterly earnings data on Wednesday, May 13th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.03. The business had revenue of $8.72 million during the quarter, compared to analysts’ expectations of $4.57 million. As a group, research analysts predict that Abeona Therapeutics Inc. will post -0.79 earnings per share for the current year.

Analyst Ratings Changes

ABEO has been the subject of several analyst reports. Stifel Nicolaus set a $17.00 target price on Abeona Therapeutics in a report on Tuesday, March 17th. Oppenheimer reaffirmed an “outperform” rating on shares of Abeona Therapeutics in a research note on Monday, March 9th. Wall Street Zen upgraded shares of Abeona Therapeutics from a “strong sell” rating to a “sell” rating in a report on Monday, June 1st. Finally, HC Wainwright restated a “buy” rating and issued a $20.00 price objective on shares of Abeona Therapeutics in a research report on Thursday, May 28th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $19.00.

Get Our Latest Stock Report on ABEO

Institutional Investors Weigh In On Abeona Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. AIGH Capital Management LLC grew its holdings in Abeona Therapeutics by 55.0% in the first quarter. AIGH Capital Management LLC now owns 3,100,000 shares of the biopharmaceutical company’s stock worth $13,888,000 after purchasing an additional 1,100,000 shares during the period. Adage Capital Partners GP L.L.C. grew its stake in shares of Abeona Therapeutics by 14.2% in the second quarter. Adage Capital Partners GP L.L.C. now owns 3,072,985 shares of the biopharmaceutical company’s stock worth $17,455,000 after acquiring an additional 381,357 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Abeona Therapeutics by 3.8% during the third quarter. Vanguard Group Inc. now owns 2,602,901 shares of the biopharmaceutical company’s stock valued at $13,743,000 after acquiring an additional 95,878 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Abeona Therapeutics by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 1,137,127 shares of the biopharmaceutical company’s stock worth $5,994,000 after purchasing an additional 9,996 shares during the last quarter. Finally, Kennedy Capital Management LLC boosted its stake in Abeona Therapeutics by 56.4% in the 3rd quarter. Kennedy Capital Management LLC now owns 1,050,863 shares of the biopharmaceutical company’s stock worth $5,549,000 after purchasing an additional 378,860 shares in the last quarter. 80.56% of the stock is owned by hedge funds and other institutional investors.

About Abeona Therapeutics

(Get Free Report)

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.